{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:26:32Z","timestamp":1791491192988,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s10067-019-04649-4","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T03:41:56Z","timestamp":1564371716000},"page":"3081-3092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3953-845X","authenticated-orcid":false,"given":"Nancy A.","family":"Shadick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Gerlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Frits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Stolshek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenna L.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Mutebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Weinblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,29]]},"reference":[{"key":"4649_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1\u201326. \nhttps:\/\/doi.org\/10.1002\/art.39480","journal-title":"Arthritis Rheumatol"},{"key":"4649_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492\u2013509. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2013-204573","journal-title":"Ann Rheum Dis"},{"key":"4649_CR3","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3899\/jrheum.110207","volume":"39","author":"VP Bykerk","year":"2012","unstructured":"Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, Khraishi M, Leclercq SA, Legare J, Mosher DP, Pencharz J, Pope JE, Thomson J, Thorne C, Zummer M, Bombardier C (2012) Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 39:1559\u20131582. \nhttps:\/\/doi.org\/10.3899\/jrheum.110207","journal-title":"J Rheumatol"},{"key":"4649_CR4","doi-asserted-by":"publisher","unstructured":"Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, Maxwell LJ, Shah NP, Tugwell P, Wells GA (2016) Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev CD012183. doi:\nhttps:\/\/doi.org\/10.1002\/14651858.CD012183","DOI":"10.1002\/14651858.CD012183"},{"key":"4649_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/rheumatology\/ker332","volume":"51","author":"E Hallert","year":"2012","unstructured":"Hallert E, Husberg M, Bernfort L (2012) The incidence of permanent work disability in patients with rheumatoid arthritis in Sweden 1990-2010: before and after introduction of biologic agents. Rheumatology (Oxford) 51:338\u2013346. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/ker332","journal-title":"Rheumatology (Oxford)"},{"key":"4649_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/annrheumdis-2011-200354","volume":"71","author":"E Krishnan","year":"2012","unstructured":"Krishnan E, Lingala B, Bruce B, Fries JF (2012) Disability in rheumatoid arthritis in the era of biological treatments. Ann Rheum Dis 71:213\u2013218. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2011-200354","journal-title":"Ann Rheum Dis"},{"key":"4649_CR7","first-page":"1532","volume":"31","author":"SW Baumgartner","year":"2004","unstructured":"Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB (2004) Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. J Rheumatol 31:1532\u20131537","journal-title":"J Rheumatol"},{"key":"4649_CR8","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YP Goekoop-Ruiterman","year":"2005","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52:3381\u20133390. \nhttps:\/\/doi.org\/10.1002\/art.21405","journal-title":"Arthritis Rheum"},{"key":"4649_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"MA Quinn","year":"2005","unstructured":"Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52:27\u201335. \nhttps:\/\/doi.org\/10.1002\/art.20712","journal-title":"Arthritis Rheum"},{"key":"4649_CR10","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/ard.2010.144139","volume":"70","author":"M Neovius","year":"2011","unstructured":"Neovius M, Simard JF, Klareskog L, Askling J (2011) Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. Ann Rheum Dis 70:1407\u20131414. \nhttps:\/\/doi.org\/10.1136\/ard.2010.144139","journal-title":"Ann Rheum Dis"},{"key":"4649_CR11","doi-asserted-by":"publisher","unstructured":"Weinblatt ME, Bathon JM, Kremer JM, Fleischmann RM, Schiff MH, Martin RW, Baumgartner SW, Park GS, Mancini EL, Genovese MC (2011) Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken) 63:373\u2013382. \nhttps:\/\/doi.org\/10.1002\/acr.20372","DOI":"10.1002\/acr.20372"},{"key":"4649_CR12","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762\u2013784. \nhttps:\/\/doi.org\/10.1002\/art.23721","journal-title":"Arthritis Rheum"},{"key":"4649_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:625\u2013639. \nhttps:\/\/doi.org\/10.1002\/acr.21641","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4649_CR14","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s10067-017-3588-7","volume":"36","author":"LR Harrold","year":"2017","unstructured":"Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM (2017) A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity\/remission in clinical practice? Clin Rheumatol 36:1215\u20131220. \nhttps:\/\/doi.org\/10.1007\/s10067-017-3588-7","journal-title":"Clin Rheumatol"},{"key":"4649_CR15","doi-asserted-by":"publisher","unstructured":"Barra L, Pope JE, Payne M (2009) Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. J Rheumatol 36:1421\u20131428. \nhttps:\/\/doi.org\/10.3899\/jrheum.081122","DOI":"10.3899\/jrheum.081122"},{"key":"4649_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3899\/jrheum.120400","volume":"40","author":"EM Dewitt","year":"2013","unstructured":"Dewitt EM, Li Y, Curtis JR, Glick HA, Greenberg JD, Anstrom KJ, Kremer JM, Reed G, Schulman KA, Reed SD (2013) Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis. J Rheumatol 40:127\u2013136. \nhttps:\/\/doi.org\/10.3899\/jrheum.120400","journal-title":"J Rheumatol"},{"key":"4649_CR17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/acr.22151","volume":"66","author":"JS Chen","year":"2014","unstructured":"Chen JS, Makovey J, Lassere M, Buchbinder R, March LM (2014) Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis. Arthritis Care Res (Hoboken) 66:464\u2013472. \nhttps:\/\/doi.org\/10.1002\/acr.22151","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4649_CR18","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/acr.22290","volume":"66","author":"C Thorne","year":"2014","unstructured":"Thorne C, Bensen WG, Choquette D, Chow A, Khraishi M, Atkins CJ, Kelsall JT, Lehman AJ, Shawi M, Khalil H, Nantel F, Rampakakis E, Sampalis JS, Otawa S (2014) Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry. Arthritis Care Res (Hoboken) 66:1142\u20131151. \nhttps:\/\/doi.org\/10.1002\/acr.22290","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4649_CR19","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/acr.22327","volume":"66","author":"A Richter","year":"2014","unstructured":"Richter A, Strangfeld A, Herzer P, Wilden E, Bussmann A, Listing J, Zink A (2014) Sustainability of rituximab therapy in different treatment strategies: results of a 3-year followup of a German biologics register. Arthritis Care Res (Hoboken) 66:1627\u20131633. \nhttps:\/\/doi.org\/10.1002\/acr.22327","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4649_CR20","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.131279","volume":"41","author":"F De Keyser","year":"2014","unstructured":"De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R (2014) Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry. J Rheumatol 41:1761\u20131765. \nhttps:\/\/doi.org\/10.3899\/jrheum.131279","journal-title":"J Rheumatol"},{"key":"4649_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ebiom.2016.08.024","volume":"11","author":"DS Courvoisier","year":"2016","unstructured":"Courvoisier DS, Alpizar-Rodriguez D, Gottenberg JE, Hernandez MV, Iannone F, Lie E, Santos MJ, Pavelka K, Turesson C, Mariette X, Choquette D, Hetland ML, Finckh A (2016) Rheumatoid arthritis patients after initiation of a new biologic agent: trajectories of disease activity in a large multinational cohort study. EBioMedicine 11:302\u2013306. \nhttps:\/\/doi.org\/10.1016\/j.ebiom.2016.08.024","journal-title":"EBioMedicine"},{"key":"4649_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40744-017-0077-z","volume":"4","author":"DA Pappas","year":"2017","unstructured":"Pappas DA, Kremer JM, Griffith J, Reed G, Salim B, Karki C, Garg V (2017) Long-term effectiveness of adalimumab in patients with rheumatoid arthritis: an observational analysis from the Corrona rheumatoid arthritis registry. Rheumatol Ther 4:375\u2013389. \nhttps:\/\/doi.org\/10.1007\/s40744-017-0077-z","journal-title":"Rheumatol Ther"},{"key":"4649_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009930","volume":"97","author":"B Armagan","year":"2018","unstructured":"Armagan B, Sari A, Erden A, Kilic L, Erdat EC, Kilickap S, Kiraz S, Bilgen SA, Karadag O, Akdogan A, Ertenli I, Kalyoncu U (2018) Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: single center real life results. Medicine (Baltimore) 97:e9930. \nhttps:\/\/doi.org\/10.1097\/MD.0000000000009930","journal-title":"Medicine (Baltimore)"},{"key":"4649_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/14397595.2017.1332558","volume":"28","author":"S Asai","year":"2018","unstructured":"Asai S, Fujibayashi T, Oguchi T, Hanabayashi M, Hayashi M, Matsubara H, Ito T, Yabe Y, Watanabe T, Hirano Y, Kanayama Y, Kaneko A, Kato T, Takagi H, Takahashi N, Funahashi K, Takemoto T, Asai N, Watanabe T, Ishiguro N, Kojima T (2018) Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: a multicenter observational cohort study. Mod Rheumatol 28:221\u2013226. \nhttps:\/\/doi.org\/10.1080\/14397595.2017.1332558","journal-title":"Mod Rheumatol"},{"key":"4649_CR25","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/rheumatology\/keu400","volume":"54","author":"LE Brown","year":"2015","unstructured":"Brown LE, Frits ML, Iannaccone CK, Weinblatt ME, Shadick NA, Liao KP (2015) Clinical characteristics of RA patients with secondary SS and association with joint damage. Rheumatology (Oxford) 54:816\u2013820. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/keu400","journal-title":"Rheumatology (Oxford)"},{"key":"4649_CR26","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/acr.21767","volume":"64","author":"JR Curtis","year":"2012","unstructured":"Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, Ramanujan S, Cavet G, Centola M, Hesterberg LK, Chernoff D, Ford K, Shadick NA, Hamburger M, Fleischmann R, Keystone E, Weinblatt ME (2012) Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 64:1794\u20131803. \nhttps:\/\/doi.org\/10.1002\/acr.21767","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4649_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/rheumatology\/keq263","volume":"50","author":"CK Iannaccone","year":"2011","unstructured":"Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, Plenge RM, Solomon DH, Weinblatt ME, Shadick NA (2011) Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women\u2019s Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford) 50:40\u201346. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/keq263","journal-title":"Rheumatology (Oxford)"},{"key":"4649_CR28","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/ard.2011.154625","volume":"71","author":"S Lillegraven","year":"2012","unstructured":"Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML, Iannaccone CK, Kvien TK, Haavardsholm EA, Weinblatt ME, Solomon DH (2012) Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR\/EULAR remission criteria in an observational cohort. Ann Rheum Dis 71:681\u2013686. \nhttps:\/\/doi.org\/10.1136\/ard.2011.154625","journal-title":"Ann Rheum Dis"},{"key":"4649_CR29","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/ng.2007.27","volume":"39","author":"RM Plenge","year":"2007","unstructured":"Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, Pe'er I, Burtt NP, Blumenstiel B, DeFelice M, Parkin M, Barry R, Winslow W, Healy C, Graham RR, Neale BM, Izmailova E, Roubenoff R, Parker AN, Glass R, Karlson EW, Maher N, Hafler DA, Lee DM, Seldin MF, Remmers EF, Lee AT, Padyukov L, Alfredsson L, Coblyn J, Weinblatt ME, Gabriel SB, Purcell S, Klareskog L, Gregersen PK, Shadick NA, Daly MJ, Altshuler D (2007) Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 39:1477\u20131482. \nhttps:\/\/doi.org\/10.1038\/ng.2007.27","journal-title":"Nat Genet"},{"key":"4649_CR30","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/archinte.166.22.2490","volume":"166","author":"NA Shadick","year":"2006","unstructured":"Shadick NA, Cook NR, Karlson EW, Ridker PM, Maher NE, Manson JE, Buring JE, Lee IM (2006) C-reactive protein in the prediction of rheumatoid arthritis in women. Arch Intern Med 166:2490\u20132494. \nhttps:\/\/doi.org\/10.1001\/archinte.166.22.2490","journal-title":"Arch Intern Med"},{"key":"4649_CR31","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/art.24551","volume":"60","author":"DH Solomon","year":"2009","unstructured":"Solomon DH, Finkelstein JS, Shadick N, LeBoff MS, Winalski CS, Stedman M, Glass R, Brookhart MA, Weinblatt ME, Gravallese EM (2009) The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis Rheum 60:1624\u20131631. \nhttps:\/\/doi.org\/10.1002\/art.24551","journal-title":"Arthritis Rheum"},{"key":"4649_CR32","doi-asserted-by":"publisher","unstructured":"Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44\u201348. \nhttps:\/\/doi.org\/10.1002\/art.1780380107","DOI":"10.1002\/art.1780380107"},{"key":"4649_CR33","doi-asserted-by":"crossref","unstructured":"van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845\u20131850. \nhttps:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/1529-0131(199810)41:10%3C1845::AID-ART17%3E3.0.CO%3B2-K","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K"},{"key":"4649_CR34","doi-asserted-by":"publisher","unstructured":"Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP (1983) Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 26:1346\u20131353. \nhttps:\/\/doi.org\/10.1002\/art.1780261107","DOI":"10.1002\/art.1780261107"},{"key":"4649_CR35","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.rdc.2009.10.008","volume":"35","author":"T Pincus","year":"2009","unstructured":"Pincus T, Yazici Y, Bergman MJ (2009) RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin N Am 35:773\u2013778, viii. \nhttps:\/\/doi.org\/10.1016\/j.rdc.2009.10.008","journal-title":"Rheum Dis Clin N Am"},{"key":"4649_CR36","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s10067-018-4140-0","volume":"37","author":"A Kavanaugh","year":"2018","unstructured":"Kavanaugh A, Singh R, Karki C, Etzel CJ, Kremer JM, Greenberg JD, Griffith J (2018) Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis. Clin Rheumatol 37:2275\u20132280. \nhttps:\/\/doi.org\/10.1007\/s10067-018-4140-0","journal-title":"Clin Rheumatol"},{"key":"4649_CR37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/art.21575","volume":"54","author":"L Klareskog","year":"2006","unstructured":"Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, Ronnelid J, Harris HE, Ulfgren AK, Rantapaa-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54:38\u201346. \nhttps:\/\/doi.org\/10.1002\/art.21575","journal-title":"Arthritis Rheum"},{"key":"4649_CR38","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1002\/art.20553","volume":"50","author":"L Padyukov","year":"2004","unstructured":"Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L (2004) A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 50:3085\u20133092. \nhttps:\/\/doi.org\/10.1002\/art.20553","journal-title":"Arthritis Rheum"},{"key":"4649_CR39","doi-asserted-by":"publisher","unstructured":"Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L, Alfredsson L, group Es (2003) Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 62:835\u2013841. \nhttps:\/\/doi.org\/10.1136\/ard.62.9.835","DOI":"10.1136\/ard.62.9.835"},{"key":"4649_CR40","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1093\/rheumatology\/ket224","volume":"52","author":"VK Ranganath","year":"2013","unstructured":"Ranganath VK, Maranian P, Elashoff DA, Woodworth T, Khanna D, Hahn T, Sarkisian C, Kremer JM, Furst DE, Paulus HE (2013) Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford) 52:1809\u20131817. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/ket224","journal-title":"Rheumatology (Oxford)"},{"key":"4649_CR41","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/acr.21940","volume":"65","author":"CK Iannaccone","year":"2013","unstructured":"Iannaccone CK, Fossel A, Tsao H, Cui J, Weinblatt M, Shadick N (2013) Factors associated with attrition in a longitudinal rheumatoid arthritis registry. Arthritis Care Res (Hoboken) 65:1183\u20131189. \nhttps:\/\/doi.org\/10.1002\/acr.21940","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04649-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04649-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04649-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T23:34:10Z","timestamp":1595892850000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04649-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,29]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["4649"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04649-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,29]]},"assertion":[{"value":"18 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"At the time of the analysis, B.S.S., D.C., and A.M. were employees and stockholders of Amgen Inc. N.M.G. and B.L.B. were employees of Health Analytics, LLC, which received funding from Amgen Inc. to conduct the study. N.A.S. has been a consultant to Bristol-Myers Squibb and has received research grants from Amgen, Mallinckrodt, UCB, Crescendo Biosciences, Sanofi, Bristol-Myers Squibb, and DxTerity. M.E.W. has been a consultant to Amgen, Bristol-Myers Squibb, Crescendo Bioscience, and UCB and has received research grants from Amgen, Bristol-Myers Squibb, Crescendo Bioscience, UCB, DxTerity, and Sanofi\/Regeneron. M.L.F., C.I, and J.C declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}